pharmacopeia
GET
/api/v1/drug/chorionic-gonadotropin

Mechanism of action

Sourced from openFDA

Mechanism-of-action class: Hormone Receptor Agonists.

Hormone Receptor

Indications

Sourced from openFDA
  • HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ‘‘NORMAL’’ DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS.ICD-10: E66.9

Contraindications

Sourced from openFDA
  • Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG.contraindicated

Dosage & administration

Sourced from openFDA

Intramuscular Use Only The dosage regimen employed in any particular case will depend upon the indication for use, the age and weight of the patient and the physician’s preference. The following regimens have been advocated by various authorities. Prepubertal Cryptorchidism Not Due To Anatomical Obstruction 4,000 USP units three times weekly for three weeks. 5,000 USP units every second day for four injections. 15 injections of 500 to 1,000 USP units over a period of six weeks. 500 USP units three times weekly for four to six weeks. If this course of treatment is not successful, another is begun one month later giving 1,000 USP units per injection. Selected Cases Of Hypogonadotropic Hypogonadism In Males 500 to 1,000 USP units three times a week for three weeks, followed by the same dose twice a week for three weeks. 4,000 USP units three times weekly for six to nine months, following which the dosage may be reduced to 2,000 USP units three times weekly for an additional three months. Induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure and who has been appropriately pretreated with human menotropins (see prescribing information for menotropins for dosage and administration for that drug product). 5,000 to 10,000 USP units one day following the last dose of menotropins. (A dosage of 10,000 units is recommended in the labeling for menotropins.) IMPORTANT: USE COMPLETELY WITHIN 60 DAYS AFTER RECONSTITUTION. REFRIGERATE AFTER RECONSTITUTION.

Warnings & precautions

Sourced from openFDA

HCG should be used in conjunction with human menopausal gonadotropins only by physicians experienced with infertility problems who are familiar with the criteria for patient selection, contraindications, warnings, precautions and adverse reactions described in the package insert for menotropins. The principal serious adverse reactions are: (1) Ovarian hyperstimulation, a syndrome of sudden ovarian enlargement, ascites with or without pain and/or pleural effusion, (2) Rupture of ovarian cysts with resultant hemoperitoneum, (3) Multiple births and (4) Arterial thromboembolism. Anaphylaxis and other hypersensitivity reactions have been reported with urinary-derived HCG products.

Adverse reactions

Sourced from openFDA

Headache, irritability, restlessness, depression, fatigue, edema, precocious puberty, gynecomastia and pain at the site of injection.

Approval history

Sourced from openFDA
  • Mar 5, 1973BLABLA017067Fresenius Kabi Usa

FAERS reports

View JSON
Reference statistics only. FAERS reports are voluntarily submitted and are not incidence rates, safety signals, or causal evidence. Counts reflect reporting volume — how often a reaction was reported, not how often it occurs. For decision-grade use, consult openFDA and the FAERS Public Dashboard directly.
544 total reports matchedLatest report Share = reports listing the reaction ÷ total matched reports. Rows can sum to >100% because a single report often lists multiple reactions.
  1. 1Ovarian Hyperstimulation Syndrome12924%
  2. 2Drug Exposure During Pregnancy376.8%
  3. 3Drug Ineffective366.6%
  4. 4Off Label Use325.9%
  5. 5Ascites315.7%
  6. 6Ectopic Pregnancy315.7%
  7. 7Dyspnoea275.0%
  8. 8Nausea275.0%
  9. 9Abdominal Distension254.6%
  10. 10Headache244.4%
  11. 11Pain244.4%
  12. 12Pleural Effusion244.4%
  13. 13Abortion Spontaneous234.2%
  14. 14Abdominal Pain213.9%
  15. 15Caesarean Section193.5%

Literature

View JSON

Recent PubMed references pinned to Chorionic Gonadotropin as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

Clinical trials

View JSON

The 10 most recently updated of 406 ClinicalTrials.gov registrations naming Chorionic Gonadotropin as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

Frequently asked questions

How does Chorionic Gonadotropin work?
Mechanism-of-action class: Hormone Receptor Agonists.
What is Chorionic Gonadotropin used for?
According to FDA labeling, Chorionic Gonadotropin carries indications including: HCG HAS NOT BEEN DEMONSTRATED TO BE EFFECTIVE ADJUNCTIVE THERAPY IN THE TREATMENT OF OBESITY. THERE IS NO SUBSTANTIAL EVIDENCE THAT IT INCREASES WEIGHT LOSS BEYOND THAT RESULTING FROM CALORIC RESTRICTION, THAT IT CAUSES A MORE ATTRACTIVE OR ‘‘NORMAL’’ DISTRIBUTION OF FAT, OR THAT IT DECREASES THE HUNGER AND DISCOMFORT ASSOCIATED WITH CALORIE-RESTRICTED DIETS.. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.
What class of drug is Chorionic Gonadotropin?
Chorionic Gonadotropin is classified as Gonadotropins, Hormone Receptor Agonists, Increased Luteinizing Hormone Secretion.
What are the brand names for Chorionic Gonadotropin?
Chorionic Gonadotropin is marketed under brand names including Chorulon, Novarel, Ovidrel, Pregnyl.
What are the contraindications for Chorionic Gonadotropin?
Chorionic Gonadotropin labeling lists contraindications including: Precocious puberty, prostatic carcinoma or other androgen-dependent neoplasm, prior allergic reaction to HCG.. Always consult the full prescribing information and a clinician.
Note. Data for chorionic-gonadotropin is illustrative MVP content compiled from public sources. pharmacopeia is for educational and informational use only and is not a substitute for professional medical advice.

Search pharmacopeia

Search drugs, classes, and ingredients